Elicio Therapeutics, Inc. (ELTX)
| Market Cap | 44.16M -70.7% |
| Revenue (ttm) | n/a |
| Net Income | -35.74M |
| EPS | -1.80 |
| Shares Out | 28.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 232,813 |
| Open | 1.590 |
| Previous Close | 1.630 |
| Day's Range | 1.550 - 1.650 |
| 52-Week Range | 1.250 - 16.000 |
| Beta | 2.00 |
| Analysts | Buy |
| Price Target | 13.00 (+733.33%) |
| Earnings Date | Nov 5, 2026 |
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ELTX stock is "Buy." The 12-month stock price target is $13.0, which is an increase of 733.33% from the latest price.
News
Elicio Therapeutics Transcript: KOL event
AMPLIFY-7P showed immune-response and subgroup signals, although its primary DFS endpoint was not met. Planned neoadjuvant and metastatic studies will test combinations and use ctDNA and immune biomarkers to guide development.
Elicio Therapeutics price target lowered to $21 from $23 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Elicio Therapeutics (ELTX) to $21 from $23 and keeps a Buy rating on the shares following the Q3 report.
Elicio Therapeutics reports Q3 EPS (30c), consensus (43c)
Reports Q3 R&D expense decreased to $4.9M from $5.0M, primarily due to lower clinical trial costs as patients moved into the follow-up phase of the Phase 2 camupepimut study, offset…
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRA...
Elicio Therapeutics Quarterly report: Q3 2026
Elicio Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Elicio Therapeutics Earnings release: Q3 2026
Elicio Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KR...
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinic...
Elicio Therapeutics reports AMPLIFY-7P study misses primary endpoint
Elicio Therapeutics (ELTX) announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut, presented in a late-breaking Proffered Paper oral session at the European Society for Medical ...
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KR...
Elicio Therapeutics Slides: Investor presentation
Elicio Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Elicio Therapeutics Proxy statement: Proxy filing
Elicio Therapeutics filed a proxy statement on October 9, 2026, providing details for shareholder voting and corporate governance matters.
Elicio Therapeutics price target lowered to $8 from $27 at B. Riley
B. Riley lowered the firm’s price target on Elicio Therapeutics (ELTX) to $8 from $27 and keeps a Buy rating on the shares. Elicio’s October 23 ESMO late-breaker is the…
Elicio Therapeutics announces Phase 2 AMPLIFY-7P data selected for ESMO ’26
Elicio Therapeutics (ELTX) announced that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in resected pancreatic ductal adenocarcinoma, PDAC, have been selected f...
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform ...
Elicio Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted advances in lymph node-targeted immunotherapy, with ELI-002 showing promising responses in metastatic pancreatic cancer and a strong safety profile. Upcoming trials will combine ELI-002 with RAS inhibitors and checkpoint inhibitors, targeting a large market of KRAS-mutant cancers.
Elicio Therapeutics Slides: Corporate presentation
Elicio Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRA...
Elicio Therapeutics Slides: Corporate presentation
Elicio Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRA...
Elicio Therapeutics reports Q2 EPS (43c), consensus (54c)
“The encouraging clinical observations reported to date, including multiple complete responses following ELI-002 7P treatment and subsequent checkpoint inhibition, further support the promise of our A...
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor ...
Elicio Therapeutics Quarterly report: Q2 2026
Elicio Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Elicio Therapeutics Earnings release: Q2 2026
Elicio Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KR...